Emcure Pharmaceuticals

Emcure Pharmaceuticals has received regulatory approvals for its draft red herring prospectus and will shortly be filing the RHP for the Rs 5,000-crore initial share sale, which will hit the market soon after the Budget, according to merchant banking sources. The IPO consists of a fresh issue of up to Rs 1,100 crore by the company, which will be used as growth capital, and an offer for sale by promoter shareholders -- founder, managing director & chief executive Satish Mehta who owns 41.92